广东医学2024，Vol.45Issue(6)：794-800,7.DOI:10.13820/j.cnki.gdyx.20234291
慢性心力衰竭临床治疗的回顾及展望
Review and prospect of clinical treatment of chronic heart failure
摘要
Abstract
Chronic heart failure usually marks the end stage of most cardiovascular diseases,and has the charac-teristics of high prevalence and extremely unfavorable prognosis.In terms of drug therapy,the"Golden Triangle"program is widely regarded as a classic strategy for the treatment of chronic heart failure.In recent years,with the publication of a large number of clinical research data,the"new quadruple"therapy for chronic heart failure and the soluble guanylate cy-clase agonist Vericiguat and other new therapeutic drugs began to be applied in the clinic.A series of biomarkers have been found that are closely related to the prognosis of patients with chronic heart failure,such as SERCA2a,neutrophil ge-latinase-associated lipid carrier protein,and growth differentiation factor 15.The discovery of these new therapies and bi-omarkers could help improve clinical outcomes and better predict prognosis in patients with chronic heart failure.This arti-cle reviews the clinical treatment and biomarkers of chronic heart failure.关键词
慢性心力衰竭/新四联疗法/鸟苷酸环化酶激动剂/SERCA2aKey words
chronic heart failure/new quadruple therapy/guanylate cyclase agonist/SERCA2a分类
医药卫生引用本文复制引用
李家昊,陈文亮,陈庞何,许锦荣..慢性心力衰竭临床治疗的回顾及展望[J].广东医学,2024,45(6):794-800,7.基金项目
湛江市科技发展专项资金竞争性分配项目(2021A05090,2022A01132) （2021A05090,2022A01132）
